The Conversation (0)
Aequus Pharmaceuticals announced the European Patent Office issued “an intention” to give the company a patent for AQS1301, Aequus’ once-weekly transdermal patch containing aripiprazole.
Aequus Pharmaceuticals (TSXV:AQS; OTCQB:AQSZF) announced the European Patent Office issued “an intention” to give the company a patent for AQS1301, Aequus’ once-weekly transdermal patch containing aripiprazole.
As quoted in the press release:
AQS1301 is in development for the treatment of certain psychiatric disorders and is intended to provide patients with a long-acting dosing alternative that is a comfortable, convenient and easy-to-use in an effort to promote medication adherence.
This is the eighth regional patent issued or granted for AQS1301, following US, Russia, Mexico, Japan, China, Canada and Australia.
“With this patent, Aequus has now achieved intellectual property that spans across all major pharmaceutical markets for its once-weekly transdermal aripiprazole program,” said Anne Stevens, COO and Director of Aequus Pharmaceuticals. “This patent grant coincides nicely with our accelerated business development efforts, as we look to further develop this program in collaboration with regional partners.”
Click here to read the full press release.
Source: www.marketwired.com
